|View printer-friendly version|
Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer
November 30, 2000 at 12:00 AM EST
Bothell, WA – November 30, 2000 – Seattle Genetics, Inc. announced the initiation of a phase II clinical trial with one of its lead drug candidates, SGN-15. The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere® for patients with hormone refractory prostate cancer. The study is planned for as many as 15 sites in the U.S. with the lead site at Arizona Cancer Center in Tucson, AZ.
About Prostate Cancer
Prostate cancer is the second leading cause of cancer related deaths in males in the U.S. The American Cancer Society estimates that there will be about 180,000 new cases of prostate cancer diagnosed in the U.S. this year.
Seattle Genetics discovers and develops monoclonal antibody, or mAb, based drugs to treat cancer and related diseases. The Company has four mAb-based technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins, and antibody-directed enzyme prodrug therapy. Using these technologies, Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company recently initiated two other phase II clinical trials with SGN-15, one for patients with advanced breast cancer and a second for patients with advanced colorectal cancer. Additionally, the Company has a collaboration with Genentech to develop certain product candidates discovered at Seattle Genetics, including SGN-14.